11 results
8-K
EX-99.1
3k83k wcrk
7 Nov 22
Verve Therapeutics Provides Regulatory Update on VERVE-101 Investigational New Drug Application and Reports Third Quarter 2022 Financial Results
7:00am
DEF 14A
lqbh8zwcvqeiq0jztbj
29 Apr 22
Definitive proxy
7:01am
10-K
1ahsg2vnlm jl4k2gc
14 Mar 22
Annual report
7:04am
S-1
EX-10.3
ko3yvthzb6qbz0w0psws
28 May 21
IPO registration
4:04pm
S-1
EX-10.17
m3w4 7qflg
28 May 21
IPO registration
4:04pm
DRS
EX-10.3
0n4gg8pdn20
16 Apr 21
Draft registration statement
12:00am
- Prev
- 1
- Next